SCHEMBL6314894

SCHEMBL6314894

O=C(O)CCNC(=O)[C]1C=CC=NC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
ITGB3 P05106 2/20 0.35
ITGA2B P08514 2/20 0.35
MAPK1 P28482 1/20 0.35
EGLN2 Q96KS0 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
MME P08473 1/20 0.33
ACE P12821 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
FABP4 P15090 1/20 0.33
ECE1 P42892 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9717434 0.64 MAPK1 (0.71) LMNAL3MBTL1CA1CA2MAPK1
SCHEMBL394245 0.64 FABP4 (0.59) LMNAL3MBTL1CA1CA2ITGB3
Butyric Acid SCHEMBL28197990 0.62 FFAR3 (0.41)
SCHEMBL12963309 0.62 NPSR1 (0.43) LMNAL3MBTL1CA1CA2ITGB3
Betamipron SCHEMBL4498475 0.61 PRSS1 (0.70) LMNACA1CA2MAPK1HPGD
Betamipron SCHEMBL605899 0.61 PRSS1 (0.70) LMNACA1CA2MAPK1HPGD
SCHEMBL3203823 0.61 CYP1A2 (0.76) L3MBTL1CA1CA2MAPK1CYP1A2
SCHEMBL27537963 0.60 EGLN1 (0.47) LMNAL3MBTL1CA1CA2EGLN2
SCHEMBL24471265 0.59 ALOX15 (0.52) LMNACA1CA2ITGB3ITGA2B
SCHEMBL12491240 0.59 KDM4E (0.72) L3MBTL1CYP1A2CYP2C9CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments GLP1R, GIPR, GCGR LMNA 2720/4885L3MBTL1 1957/4885CA1 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.